W
WAVEMAN · COMPANY
ARTV · Artiva Biotherapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

ARTV

Artiva Biotherapeutics, Inc.
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001817241
CLUSTER · 5 INSIDERSFORM 144 · 2☆ WATCH
INSIDER NET · 180D
$107.7M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
5
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
66
13F, latest reported quarter
REVENUE GROWTH
-100.0%
XBRL, annual
NET MARGIN
-
CONVERSIONS · 180D
2
codes C/M, not in net · $11.0K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$107.7M over 180 days
+$16.7M over 90 days · +$109.2M of it by a 10%+ holder
more than 99% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
66 funds added or opened last quarter
more than 51% of Pharma & Biotech
REVENUE
-100.0% year over year
the lowest in Pharma & Biotech
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
3.9% of shares outstanding short · 5.1 days to cover · settled 2026-07-31
below 52% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
5 insiders bought a net $107.7M, but 2 Form 144 notices ($101.8K) are queued to sell.
66 funds added or opened positions in the latest 13F quarter, of 74 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +262.1%
+262.1%12M
-26%+94%+213%+333%2025-092025-102025-122026-032026-052026-072026-09 2026-05-11 · RA Capital Nexus Fund III, L.P. bought $75.0M2026-05-11 · GC Corp. bought $12.5M2026-06-11 · RA Capital Nexus Fund, L.P. bought $4.3M2026-05-11 · GC Corp. bought $4.0M2026-06-12 · Kolchinsky Peter bought $3.4M2026-06-09 · RA Capital Nexus Fund, L.P. bought $3.3M2026-07-16 · RA CAPITAL MANAGEMENT, L.P. bought $1.4M2026-07-21 · RA CAPITAL MANAGEMENT, L.P. bought $1.2M2026-06-16 · Kolchinsky Peter bought $1.1M2026-07-22 · RA CAPITAL MANAGEMENT, L.P. bought $835.4K2026-09-03 · Aslan Fred sold $690.4K2026-07-23 · RA CAPITAL MANAGEMENT, L.P. bought $596.4K2026-07-24 · RA CAPITAL MANAGEMENT, L.P. bought $412.8K2026-06-25 · RA CAPITAL MANAGEMENT, L.P. bought $275.3K2026-07-31 · RA CAPITAL MANAGEMENT, L.P. bought $247.7K2026-05-19 · Aslan Fred sold $244.3K2026-07-29 · RA CAPITAL MANAGEMENT, L.P. bought $208.0K2025-10-17 · Aslan Fred sold $153.0K2026-06-15 · Kolchinsky Peter bought $138.6K2026-07-10 · RA CAPITAL MANAGEMENT, L.P. bought $135.5K2026-09-03 · Horan Christopher sold $115.6K2026-08-27 · Banerjee Subhashis sold $98.7K2026-09-03 · Bush Jennifer sold $93.6K2026-05-19 · Bush Jennifer sold $79.2K2026-07-17 · RA CAPITAL MANAGEMENT, L.P. bought $70.5K2026-05-19 · Banerjee Subhashis sold $63.4K2026-05-19 · Horan Christopher sold $63.1K2026-07-13 · RA CAPITAL MANAGEMENT, L.P. bought $58.6K2026-07-13 · RA CAPITAL MANAGEMENT, L.P. bought $58.3K2026-05-19 · Raymon Heather sold $27.9K2025-11-17 · Aslan Fred sold $21.5K2025-12-15 · Aslan Fred sold $19.1K2026-06-26 · RA CAPITAL MANAGEMENT, L.P. bought $16.8K2026-09-03 · Banerjee Subhashis sold $12.3K2026-08-18 · Banerjee Subhashis sold $5.1K2026-06-10 · RA Capital Nexus Fund, L.P. bought $7212026-08-27 · SUBHASHIS BANERJEE filed to sell $92.0K2026-08-18 · SUBHASHIS BANERJEE filed to sell $9.8K
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
5 insiders reported buying shares.
The record shows a net $107.7M bought by insiders over 180 days, 66 funds added last quarter, $101.8K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Artiva Biotherapeutics, Inc. insiders bought a net $107.7M of stock across 45 Form 4 purchases and sales, with 5 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Aslan Fred
Chief Executive Officer
SELL
2026-09-03
61,888.0
$690.4K
Bush Jennifer
COO, CLO, Compliance Officer
SELL
2026-09-03
8,391.0
$93.6K
Banerjee Subhashis
Chief Medical Officer
SELL
2026-09-03
1,100.0
$12.3K
Horan Christopher
Chief Tech Operations Officer
SELL
2026-09-03
10,366.0
$115.6K
Banerjee Subhashis
Chief Medical Officer
SELL
2026-08-27
8,222.0
$98.7K
45 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 40 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
RA CAPITAL MANAGEMENT, L.P.
17,955,642.0 sh
$174.2M
VIKING GLOBAL INVESTORS LP
2,604,166.0 sh
$25.3M
Blackstone Inc.
2,403,437.0 sh
$23.3M
5AM Venture Management, LLC
2,353,304.0 sh
$22.8M
Venrock Adviser, LLC
2,043,596.0 sh
$19.8M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
SUBHASHIS BANERJEE
FILED 2026-08-27
$92.0K
SUBHASHIS BANERJEE
FILED 2026-08-18
$9.8K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Simplify Propel Opportunities ETF
$149.6K POSITION · AS OF 2026-03-31
0.2%
Franklin Biotechnology Discovery Fund
$2.0M POSITION · AS OF 2026-04-30
0.2%
Ultra-Small Company Market Fund
$225.4K POSITION · AS OF 2026-03-31
0.2%
Nationwide Bailard Small Cap Value Fund
$212.0K POSITION · AS OF 2026-04-30
0.2%
iShares Micro-Cap ETF
$57.0K POSITION · AS OF 2026-03-31
0.0%
1290 VT Micro Cap Portfolio
$5.9K POSITION · AS OF 2026-03-31
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 4 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 1
1 ACTIVE
1
Phase 2
1 ACTIVE
2
Multi-phase
0 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-12
REVENUE$0$251.0K$32.9M
OPERATING INCOME$-89.8M$-67.3M$-30.7M
NET INCOME$-83.9M$-65.4M$-28.7M
EPS (DILUTED)-3.43-5.81-35.78
OPERATING CASH FLOW$-76.8M$-55.0M$-47.4M
CASH$26.7M$40.2M$53.5M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →